ZYME · Nasdaq · CIK 0001937653

Zymeworks Inc.

Zymeworks Inc.’s most recent SEC filing in our snapshot is a Form ARS filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $106.0M and net income of -$81.1M, according to its XBRL data on EDGAR. Its EDGAR record lists 22 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$106.0M
Net income, FY2025
-$81.1M
Form 4 filings on record, past 12 months
22

Company overview

Legal name (as filed)
Zymeworks Inc.
Ticker
ZYME
SEC Central Index Key (CIK)
0001937653
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
MIDDLETOWN, DE
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#1968 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Zymeworks Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$26.7MFY2021$412.5MFY2022$76.0MFY2023$76.3MFY2024$106.0MFY2025
Net income
-$211.8MFY2021$124.3MFY2022-$118.7MFY2023-$122.7MFY2024-$81.1MFY2025
ZYME annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$26.7M$412.5M$76.0M$76.3M$106.0M
Net income-$211.8M$124.3M-$118.7M-$122.7M-$81.1M
Diluted EPS-$4.61$1.90-$1.72-$1.62-$1.08
Total assets$389.1M$648.7M$580.9M$463.1M$346.5M
Cash and equivalents$201.9M$400.9M$157.6M$66.1M$41.2M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ZYME latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 2, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 23, 20268-KMaterial agreement; Regulation FD disclosure· period Oct 22, 2026Document · Index
Oct 26, 2026DEF 14ADefinitive proxy statement· period Dec 15, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Zymeworks Inc., by form type:

8-K ×104 ×83 ×6144 ×4SCHEDULE 13G/A ×310-Q ×2ARS ×1DEFA14A ×1DEF 14A ×1PRE 14A ×1SCHEDULE 13G ×110-K ×1S-8 ×1
ZYME recent filings
FiledFormWhat it isOriginal
Oct 26, 2026ARSARS· period Dec 31, 2025Document · Index
Oct 26, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Oct 26, 2026DEF 14ADefinitive proxy statement· period Dec 15, 2026Document · Index
Oct 23, 20268-KMaterial agreement; Regulation FD disclosure· period Oct 22, 2026Document · Index
Oct 16, 2026PRE 14APRE 14A· period Dec 15, 2026Document · Index
Oct 9, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 9, 2026Document · Index
Oct 9, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 23, 20268-KMaterial agreement; Acquisition or disposition completed; New financial obligation; Regulation FD disclosure· period Sep 23, 2026Document · Index
Aug 25, 20268-KRegulation FD disclosure; Other events· period Aug 25, 2026Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations; Regulation FD disclosure· period Aug 6, 2026Document · Index
Jul 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 6, 2026Document · Index
Jun 29, 20268-KMaterial agreement; Regulation FD disclosure· period Jun 28, 2026Document · Index
May 15, 20264Statement of changes in beneficial ownership (insider trade)· period May 13, 2026Document · Index
May 15, 20263Initial statement of beneficial ownership· period May 13, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 14, 20268-KRegulation FD disclosure; Other events· period May 14, 2026Document · Index
May 7, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 7, 20268-KResults of operations; Regulation FD disclosure· period May 7, 2026Document · Index
Apr 15, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Apr 10, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 9, 2026Document · Index
Apr 10, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 9, 2026Document · Index
Apr 10, 20263Initial statement of beneficial ownership· period Apr 9, 2026Document · Index
Apr 10, 20263Initial statement of beneficial ownership· period Apr 9, 2026Document · Index
Apr 7, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 6, 2026Document · Index
Apr 7, 20263Initial statement of beneficial ownership· period Apr 1, 2026Document · Index
Apr 1, 20268-KDirector or officer change· period Mar 31, 2026Document · Index
Mar 6, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 2, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 2, 20268-KResults of operations; Regulation FD disclosure· period Mar 2, 2026Document · Index
Mar 2, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 2, 20268-KMaterial agreement; New financial obligation; Regulation FD disclosure· period Mar 2, 2026Document · Index
Feb 17, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 13, 2026144Notice of proposed sale of securitiesDocument · Index
Feb 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 12, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 2, 20263Initial statement of beneficial ownership· period Feb 1, 2026Document · Index
Jan 13, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 13, 20263Initial statement of beneficial ownership· period Jan 9, 2026Document · Index
Jan 13, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index

Insider filing activity

22 Form 4 filings appear in Zymeworks Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Delaware

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001937653 and XBRL company facts. Zymeworks Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.